Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 4Not yet recruiting 2Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Genitourinary 1

Conditions

Solid Tumors 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1

Interventions

Cyclophosphamide 21fludarabine 17Specimen Handling 13Magnetic Resonance Spectroscopy 10pembrolizumab 9Nivolumab 9Radiotherapy 7Cisplatin 7fludarabine phosphate 5Injections 5tislelizumab 4daratumumab 4Rituximab 4Paclitaxel 4Ipilimumab 4Interleukin-2 4Immune Checkpoint Inhibitors 4Gemcitabine 4Fluorouracil 4Drug Therapy 4Doxorubicin 4Dexamethasone 4Carboplatin 4Biopsy 4venetoclax 3toripalimab 3X-Rays 3Radiosurgery 3Platinum 3Oxaliplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × Lutetium × Clear all
NCT07244393 2025-11-24

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Cellbion Co., Ltd.

Phase 1 Not yet recruiting
30 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT06553846 2024-08-14

A Clinial Trial of Lutetium [177Lu]-FAP-75 for the Treatment of Patients With Advanced Solid Tumors

Fudan University

Phase 1 Not yet recruiting
50 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡